303 related articles for article (PubMed ID: 15598482)
1. Retrospective study of the renal effects of amphotericin B lipid complex when used at higher-than-recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections.
Hooshmand-Rad R; Reed MD; Chu A; Gotz V; Morris JA; Weinberg J; Dominguez EA
Clin Ther; 2004 Oct; 26(10):1652-62. PubMed ID: 15598482
[TBL] [Abstract][Full Text] [Related]
2. Study of renal safety in amphotericin B lipid complex-treated patients.
Alexander BD; Wingard JR
Clin Infect Dis; 2005 May; 40 Suppl 6():S414-21. PubMed ID: 15809928
[TBL] [Abstract][Full Text] [Related]
3. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
Aguado JM; Lumbreras C; González-Vidal D;
Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
[TBL] [Abstract][Full Text] [Related]
4. Use of amphotericin B lipid complex in elderly patients.
Hooshmand-Rad R; Chu A; Gotz V; Morris J; Batty S; Freifeld A
J Infect; 2005 May; 50(4):277-87. PubMed ID: 15845425
[TBL] [Abstract][Full Text] [Related]
5. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies.
Mehta J; Kelsey S; Chu P; Powles R; Hazel D; Riley U; Evans C; Newland A; Treleaven J; Singhal S
Bone Marrow Transplant; 1997 Jul; 20(1):39-43. PubMed ID: 9232254
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses.
Wingard JR
Bone Marrow Transplant; 1997 Feb; 19(4):343-7. PubMed ID: 9051244
[TBL] [Abstract][Full Text] [Related]
7. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation.
Jansen J; Akard LP; Wack MF; Thompson JM; Dugan MJ; Leslie JK; Mattison R
Mycoses; 2006 Sep; 49(5):397-404. PubMed ID: 16922792
[TBL] [Abstract][Full Text] [Related]
8. Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis.
Sundar S; Goyal AK; Mandal AK; Makharia MK; Singh VP; Murray HW
J Assoc Physicians India; 1999 Feb; 47(2):186-8. PubMed ID: 10999086
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Candida infections with amphotericin B lipid complex.
Ito JI; Hooshmand-Rad R
Clin Infect Dis; 2005 May; 40 Suppl 6():S384-91. PubMed ID: 15809924
[TBL] [Abstract][Full Text] [Related]
10. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
Mattiuzzi GN; Kantarjian H; Faderl S; Lim J; Kontoyiannis D; Thomas D; Wierda W; Raad I; Garcia-Manero G; Zhou X; Ferrajoli A; Bekele N; Estey E
Cancer; 2004 Feb; 100(3):581-9. PubMed ID: 14745876
[TBL] [Abstract][Full Text] [Related]
11. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS.
Sharkey PK; Graybill JR; Johnson ES; Hausrath SG; Pollard RB; Kolokathis A; Mildvan D; Fan-Havard P; Eng RH; Patterson TF; Pottage JC; Simberkoff MS; Wolf J; Meyer RD; Gupta R; Lee LW; Gordon DS
Clin Infect Dis; 1996 Feb; 22(2):315-21. PubMed ID: 8838189
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of the dosage of amphotericin B lipid complex for the treatment of invasive fungal infections.
Linden P; Lee L; Walsh TJ
Pharmacotherapy; 1999 Nov; 19(11):1261-8. PubMed ID: 10555932
[TBL] [Abstract][Full Text] [Related]
13. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients.
Chandrasekar PH; Ito JI
Clin Infect Dis; 2005 May; 40 Suppl 6():S392-400. PubMed ID: 15809925
[TBL] [Abstract][Full Text] [Related]
14. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
Rieger CT; Dittmer M; Ostermann H
Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA).
Ito JI; Chandrasekar PH; Hooshmand-Rad R
Bone Marrow Transplant; 2005 Nov; 36(10):873-7. PubMed ID: 16113663
[TBL] [Abstract][Full Text] [Related]
16. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex.
Perfect JR
Clin Infect Dis; 2005 May; 40 Suppl 6():S401-8. PubMed ID: 15809926
[TBL] [Abstract][Full Text] [Related]
17. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
[TBL] [Abstract][Full Text] [Related]
18. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
[TBL] [Abstract][Full Text] [Related]
19. Safety evaluation of ABELCET, an amphotericin B lipid complex (ABLC): toxicity studies in rats.
Zhang Z; Diener RM; Lipman JM
Int J Toxicol; 2006; 25(4):285-94. PubMed ID: 16815817
[TBL] [Abstract][Full Text] [Related]
20. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
López-Vélez R; Videla S; Márquez M; Boix V; Jiménez-Mejías ME; Górgolas M; Arribas JR; Salas A; Laguna F; Sust M; Cañavate C; Alvar J;
J Antimicrob Chemother; 2004 Mar; 53(3):540-3. PubMed ID: 14739148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
